Investor Alley Inc.

Morning Active Runners: (NASDAQ: OCLR), (NYSE: NAVR)


New York, NY -- (ReleaseWire) -- 02/01/2013 --Oclaro, Inc. (NASDAQ: OCLR), a provider of optical components, modules and subsystems, announced the financial results for its second quarter of fiscal year 2013, which ended December 29, 2012. Oclaro closed its merger with Opnext, Inc. on July 23, 2012. The financial results for the second quarter of fiscal 2013 include a full quarter of operating results of Opnext.

Revenues were $159.5 million for the second quarter of fiscal 2013, compared with revenues of $148.8 million in the first quarter of fiscal 2013. Pro forma combined revenues for the first quarter of fiscal 2013, including Opnext for the full quarter, were $160.2 million.

Oclaro, Inc. (OCLR) is one of the largest providers of lasers and optical components, modules and subsystems for the optical communications, industrial and consumer laser markets.

Find out more on OCLR here:

Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) announced that it has priced an underwritten sale of common stock in a transaction led by J.P. Morgan Asset Management and involving one other institutional investor.

In the offering 1,542,389 shares were sold in an at market transaction at a price of $3.10 per share for gross proceeds of approximately $4.8 million.

“We are excited that J.P. Morgan Asset Management and another institution, premier investors in the biotechnology sector, have decided to establish meaningful positions in Navidea,” said Dr. Mark Pykett, President and CEO of Navidea.

Navidea Biopharmaceuticals, Inc. (NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents.

Find out where NAVB could be headed by getting the free full report here:

About issues momentum alerts on stocks that can provide gains to day traders. provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.Through a vast network of IR professionals is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the newsletter and receiving alerts from a Pro-Active team of researchers. Wall Street Report believes traders should have a chance at successfully trading Penny Stocks and invites traders and investors to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here:

Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetreport.Net website, for complete risks and disclosures.

BlueLys, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.

Contact Info:
Michael Baine